SEC Company Response from PAVmed Inc. (PAVM) (CIK 0001624326) (PAVM) — Oct 4, 2017
PAVmed Inc. (PAVM) (CIK 0001624326)
Date: Oct. 4, 2017 · CIK: 0001624326 · Accession: 0001493152-17-011231
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220549
Letter
Re: PAVmed Inc.
PAVMED INC.
One Grand Central Place, Suite 4600
New York, New York 10165
October 4, 2017
Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Registration Statement on Form S-3
Filed September 21, 2017
File No. 333-220549
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PAVmed Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement (File No. 333-220549), so that such Registration Statement will become effective at 4:30 p.m. Eastern Time on Friday, October 6, 2017, or as soon thereafter as practicable.
In connection with the Company’s request for acceleration of the effectiveness of the above-referenced Registration Statement, the Company acknowledges the following:
● should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
PAVMED
INC.
Show Raw Text
CORRESP
1
filename1.htm
PAVMED
INC.
One
Grand Central Place, Suite 4600
New
York, New York 10165
October
4, 2017
Securities
and Exchange Commission
Division
of Corporation Finance
Washington,
DC 20549
Re:
PAVmed
Inc.
Registration
Statement on Form S-3
Filed
September 21, 2017
File
No. 333-220549
Ladies
and Gentlemen:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, PAVmed Inc. (the “Company”) hereby requests
acceleration of the effectiveness of the above-referenced Registration Statement (File No. 333-220549), so that such Registration
Statement will become effective at 4:30 p.m. Eastern Time on Friday, October 6, 2017, or as soon thereafter as practicable.
In
connection with the Company’s request for acceleration of the effectiveness of the above-referenced Registration Statement,
the Company acknowledges the following:
●
should
the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
●
the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not
relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
●
the
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
Sincerely,
PAVMED
INC.
By:
/s/
Lishan Aklog, M.D.
Name:
Lishan
Aklog, M.D.
Title:
Chairman
and Chief Executive Officer